[
    [
        {
            "time": "2018-06-25",
            "original_text": "Look at Eli Lilly’s Valuations on June 25",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "valuations"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Look at Eli Lilly’s Valuations on June 25",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-06-25",
            "original_text": "AHS 2018: Lilly's Emgality™ (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA)",
            "features": {
                "keywords": [
                    "Emgality",
                    "galcanezumab-gnlm",
                    "migraine",
                    "BOTOX"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AHS 2018: Lilly's Emgality™ (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA)",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 8,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-06-25",
            "original_text": "AHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache",
            "features": {
                "keywords": [
                    "Phase 3",
                    "positive results",
                    "episodic cluster headache"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 8,
                "Source_Recency": 2
            }
        },
        {
            "time": "2018-06-25",
            "original_text": "Top Research Reports for Amazon, Intel & Eli Lilly",
            "features": {
                "keywords": [
                    "Amazon",
                    "Intel",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "semiconductors",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Top Research Reports for Amazon, Intel & Eli Lilly",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]